In models where CIITA, the master regulator of MHC-II, is expressed, dual anti-LAG-3/PD-1 ICI treatment has exhibited profound antitumor effects and inhibited tumor growth in mice, resulting in stronger IFN-γ production and enhanced cytotoxicity of CD8+ T cells (38). Here, PDCD1 is linked to neoplasm.